Inflammatory mediators and chemoattractants

Schröder, Jens‐Michael

doi:10.1016/0738-081x(95)93820-e

Cited by 14 publications

(5 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our laboratory scale matieral from affected skin was investigated for the presence of proinflammatory and/or mi togenic mediators [10], Patients' scales in contrast to stra tum comeuni from other diseases including atopic dermat itis, ichthyosis congenita, eczema or normal heel callus proved to be highly susceptible to extraction procedures for peptides in the range of 6-15 kD. Among the cytokines de tected and characterized so far in psoriatic skin, IL-8 and MGSA/GROa were the most abundant cytokines with neu trophil-and T-cel 1-activating capacities.…”

Section: Ytokine Smentioning

confidence: 99%

“…Clinical (and possibly pathoge netic) heterogeneity includes nonpustular psoriasis of early onset vs. late onset, psoriatic erythroderma, guttate vs. plaque psoriasis, pustular forms, psoriatic arthropathy, as well as drug-induced and HIV-associated psoriasis. Addi tional features include characteristic histopathological changes [2,3], strong association with MHC class-1 and class-II markers [4][5][6][7], evidence for T-cell-mediated im mune dysregulation as well as the presence of an unusually large spectrum of different regulatory mediators including cytokines, chemokines and growth factors [8][9][10], More over psoriasis of sudden eruptive onset (guttate psoriasis) is K A R G E R a 19% S. Karger AG. Basel I W M W J L '…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Immunopathology of Psoriasis

Christophers

1996

Int Arch Allergy Immunol

126

101

View full text Add to dashboard Cite

Psoriasis affects approximately 2% of the population in Western countries. Although clinically rather monomorphic, the disease presents with a number of phenotypically distinct and heterogeneous subgroups showing differences in their pathogenetic pathways. Patients with type I (early onset) psoriasis demonstrate inflammatory lesions with epidermal hyperproliferation and the presence of activated T cells as well as intraepidermal polymorphs as principal features. In contrast to pustular types of psoriasis, these patients show genetic susceptibility and strong association with MHC class I and class-I haplotypes. There is evidence for a T-cell-mediated pathomechanism leading to a large spectrum of regulatory mediators including cytokines and growth factors as well as lipid mediators which are abnormally expressed. Pathogenetically psoriasis shows features in common with chronic relapsing T-cell-mediated diseases including Crohn’s disease, rheumatoid arthritis and others.

show abstract

Section: Ytokine Smentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Immunopathology of Psoriasis

Christophers

1996

Int Arch Allergy Immunol

126

101

View full text Add to dashboard Cite

show abstract

“…In bacterial skin infections, where we see neutrophils as the overwhelming leukocyte type of the tissue cell infiltrates, it is believed that bacteria release formylated methionyl-peptides as well as (indirectly) activated C5-complement split products such as leukocyte attractants, which are both highly active neutrophil attractants and activators (for a review see Schröder, 1995) and which may thus explain the histology finding.…”

Section: Introductionmentioning

confidence: 99%

The Role of Chemokines in Cutaneous Allergic Inflammation

Schröder¹,

Mochizuki²

1999

Biological Chemistry

View full text Add to dashboard Cite

Eosinophils are the major effector cells that kill helminthic parasites and are - for unknown reasons present in the dermal part of atopic skin. This review summarizes our knowledge on the chemotactic factors involved in eosinophil tissue recruitment, focusing on the role of eosinophil-chemotactic chemokines. It is the current view that the chemokines RANTES and eotaxin represent the most important eosinophil-attracting chemokines. The inducibility of eotaxin in dermal fibroblasts only upon stimulation with Th2-cytokines IL-4 and IL-13 may explain why eosinophils appear only in the dermis and why the presence of Th2-cytokines is always linked with tissue eosinophilia.

show abstract

“… 1–3 The invasion of PMN in the psoriatic epidermis is induced by several chemoattractants, which are present in the epidermis in large amounts. 4 , 5 The most potent chemoattractant is leukotriene B4 (LTB 4 ), a pro‐inflammatory mediator derived from the 5‐lipoxygenase‐dependent metabolism of arachidonic acid. 6–9 The application of LTB 4 on normal human skin results in the dose‐dependent induction of microabscesses.…”

mentioning

confidence: 99%

VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis

Mommers

Rossum

Kooijmans-Otero

et al. 2000

British Journal of Dermatology

View full text Add to dashboard Cite

Leukotriene B4 (LTB4) receptor antagonists have been the subject of several studies in the treatment of inflammatory diseases, including psoriasis. A novel oral LTB4 antagonist, VML 295 (LY-293111) has recently been developed and has a pronounced effect on epidermal inflammatory parameters. However, oral treatment of psoriasis for 4 weeks did not result in a decrease in disease severity. The present study was performed in order to investigate whether prolonged treatment with VML 295 up to 8 weeks has a beneficial effect on the overall severity of psoriasis. Moreover, we studied to what extent VML 295 is able to prevent relapse in psoriasis. In the present study, 35 patients with stable chronic plaque psoriasis were included. A representative plaque of at least 16 cm2 was initially treated with clobetasol-17-propionate lotion under hydrocolloid occlusion in all patients. Clearance was achieved within 6 weeks in 31 patients. After clearance, the patients were randomized to treatment and received oral VML 295 capsules 200 mg twice daily or placebo for 8 weeks. Twenty-five patients completed the study. The psoriasis area and severity index (PASI) was assessed before treatment, at clearance, and on days 15, 29, 43 and 5 7 of the treatment period. Biopsies were taken from the treated lesion before treatment, after clearance and at relapse, and cells were analysed by flow cytometry with markers for differentiation (keratin 10), inflammation (vimentin), and proliferation (DNA content). After 8 weeks of treatment, 14 of 15 VML 295-treated patients had relapsed and 11 of 16 placebo-treated patients had relapsed. A total of six patients were withdrawn. The time to relapse and the number of relapsed patients was not significantly different comparing the treatment groups. There was no significant difference in PASI scores between VML 295-treated patients and placebo-treated patients after 8 weeks of treatment. Flow cytometric parameters for differentiation, inflammation and proliferation did not show significant differences between VML 295- and placebo-treated patients. We conclude that oral VML 295 (LY-293111) is not effective in preventing relapse in psoriasis, either clinically or at the cellular level, and that in our group of patients VML 295 had no beneficial effect on overall psoriasis severity. Moreover, we conclude that further development of LTB4 modulating drugs for the treatment of psoriasis is not indicated.

show abstract

Inflammatory mediators and chemoattractants

Cited by 14 publications

References 88 publications

The Immunopathology of Psoriasis

The Immunopathology of Psoriasis

The Role of Chemokines in Cutaneous Allergic Inflammation

VML 295 (LY-293111), a novel LTB4 antagonist, is not effective in the prevention of relapse in psoriasis

Contact Info

Product

Resources

About